Can CONNEQT Sustain Rapid Pulse Sales Growth Amid Production Scaling Challenges?
CONNEQT Health reports robust sales momentum for its CONNEQT Pulse arterial health monitor, with quarterly sales growth exceeding 50% and a fresh order for 10,000 units to meet rising demand.
- Over 50% quarter-on-quarter sales growth since January 2025 launch
- September quarter sales reached US$325,000
- Annualized revenue run-rate surpasses A$5.4 million
- New purchase order for 10,000 additional Pulse units
- Anticipated further sales acceleration in Q2 FY26
Strong Sales Trajectory Since Launch
CONNEQT Health Limited (ASX, CQT) has revealed a compelling sales update for its CONNEQT Pulse arterial health monitor, launched earlier this year in January 2025. The company reported a consistent and accelerating growth pattern, with sales increasing by more than 50% quarter-on-quarter. The September quarter alone generated US$325,000 in revenue, reflecting growing consumer adoption and heightened clinical recognition of the device’s value.
Scaling Production to Meet Demand
In response to this surge, CONNEQT has placed a substantial new purchase order for 10,000 additional Pulse units with its supply partner. This move underscores the company’s confidence in sustained demand and its commitment to scaling production capabilities. The annualized revenue run-rate now exceeds A$5.4 million, a significant milestone achieved in under three quarters since the product’s commercial debut.
Strategic Focus on Growth and Recurring Revenue
CEO Craig Cooper highlighted the rapid scaling of sales as a validation of the market opportunity for advanced arterial health monitoring technology. Looking ahead, CONNEQT plans to leverage seasonal demand and upcoming marketing initiatives to further accelerate sales in the second quarter of fiscal 2026. Additionally, the company is focused on optimizing marketing efficiency and introducing subscription-based and data-driven features designed to enhance recurring revenue streams.
Market Implications and Outlook
The strong sales momentum and expanding installed base position CONNEQT well within the competitive medical device landscape, particularly in the growing vascular health segment. The company’s ability to scale production and refine its marketing approach will be critical to sustaining this growth trajectory. Investors will be watching closely to see how effectively CONNEQT can convert early market traction into long-term profitability and brand leadership.
Bottom Line?
CONNEQT’s accelerating Pulse sales and production scale-up set the stage for a pivotal growth phase in FY26.
Questions in the middle?
- How will CONNEQT balance production scale with supply chain risks amid rising demand?
- What impact will new subscription and data features have on recurring revenue?
- Can CONNEQT sustain its rapid sales growth beyond seasonal and marketing boosts?
